1. DSpace at Riga Stradiņš University
2. Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure
3. Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Title:	A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19
Authors:	Kim, Alfred H.J. COVID-19 Global Rheumatology Alliance Inita, Bulina
Keywords:	3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;Internal Medicine
Issue Date:	16-Jun-2020
Citation:	Kim , A H J , COVID-19 Global Rheumatology Alliance & Inita , B 2020 , ' A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19 ' , Annals of Internal Medicine , vol. 172 , no. 12 , pp. 819-821 . https://doi.org/10.7326/M20-1223
Description:	Funding Information: Disclosures: Dr. Kim reports personal fees from Exagen Diagnostics and GlaxoSmithKline and grants from the National Institutes of Health and the Rheumatology Research Foundation outside the submitted work. Dr. Sparks reports grants from the National Institute of Allergy and Infectious Diseases Autoimmune Centers of Excellence, National Institutes of Health, during the conduct of the study and personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum outside the submitted work. Dr. Berenbaum reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, No-vartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica, and 4P Pharma outside the submitted work. Dr. Korsten reports personal fees from GlaxoSmith-Kline, Sanofi-Aventis, Pfizer, AbbVie, Novartis Pharma, Lilly, and Bristol-Myers Squibb outside the submitted work. Dr. Sat-tui reports funding from a Vasculitis Clinical Research Consortium (VCRC)/Vasculitis Foundation Fellowship. The VCRC is part of the Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Research, National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54 AR057319). Dr. Ugarte-Gil reports grants from Pfizer and Janssen outside the submitted work. Dr. Grainger reports nonfinancial support from Pfizer Australia and Janssen Australia and personal fees from Pfizer Australia, Cornerstones, Janssen New Zealand, and Novartis outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www .acponline.org/authors/icmje/ConflictOfInterestForms.do?ms Num=M20-1223.
DOI:	10.7326/M20-1223
ISSN:	0003-4819
Appears in Collections:	Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.